Shiba Masahiro, Takatera Hiroshi, Fujii Takahiro, Tokizane Takashi, Shimizu Kiyonori, Tushima Juichi
Urologic Clinic, Yao Tokusyukai General Hospital.
Hinyokika Kiyo. 2004 Jan;50(1):15-9.
Intraarterial chemotherapy (IAC) was carried out on patients with invasive bladder carcinoma to treat the bladder carcinoma while preserving the bladder. Fifteen patients with bladder carcinoma at stage T2-T4 were treated with intraarterial cisplatin (CDDP: 70 mg/m2) and adriamycin (ADM: 30 mg/m2) every 3 to 4 weeks. The response was observed in all 15 patients. Ten (66.7%) achieved a complete response (CR), and 3 (20.0%) obtained a partial response (PR). With a mean follow-up of 22.6 months, the overall survival rate was 86.7% and 12 patients were alive with functioning bladder. One patient received radical cystectomy. Although further studies and long-term follow up are required to clarify its effectiveness, IAC for patients with invasive bladder carcinoma might be an effective therapy with a preserved bladder.
对浸润性膀胱癌患者进行动脉内化疗（IAC）以治疗膀胱癌并保留膀胱。15例T2 - T4期膀胱癌患者每3至4周接受动脉内顺铂（CDDP：70 mg/m²）和阿霉素（ADM：30 mg/m²）治疗。15例患者均观察到反应。10例（66.7%）达到完全缓解（CR），3例（20.0%）获得部分缓解（PR）。平均随访22.6个月，总生存率为86.7%，12例患者存活且膀胱功能良好。1例患者接受了根治性膀胱切除术。尽管需要进一步研究和长期随访以阐明其有效性，但IAC对于浸润性膀胱癌患者可能是一种保留膀胱的有效治疗方法。
